在患有囊性纤维化症的成年人中,elexacaftor/tezacaftor/ivacaftor疗法期间,血中的化学激素水平下降
Dirk Westhölter1, Johannes Pipping1, Jonas Raspe1
1Department of Pulmonary Medicine, University Hospital Essen- Ruhrlandklinik, Essen, Germany.
Heliyon
|January 4, 2024
概括
三重CFTR调制剂疗法elexacaftor/tezacaftor/ivacaftor (ETI) 在囊性纤维化患者中显著降低了特定的炎症化学因子. 这证明了ETI的存在.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 囊性纤维化 (CF) 涉及免疫失调,炎症和感染.
- CFTR调节器疗法针对潜在的蛋白质缺陷,改善患者的临床结果.
- 这项研究研究了elexacaftor/tezacaftor/ivacaftor (ETI) 对CF相关炎症的影响,特别是全身化基因.
研究的目的:
- 分析三重CFTR调制剂疗法 (ETI) 对CF患者全身化基因水平的影响.
- 评估在CF患者中ETI发病后,促炎性化学因子的变化.
主要方法:
- 来自51名CF患者的血样本使用基于珠子的免疫试验进行了分析.
- 在开始ETI治疗之前,以及在开始ETI治疗后的3个月和6个月后,量化了化莫金水平.
- 测量的关键化学因子包括IL-8,MIP-3α,GROα,ENA-78和I-TAC.
主要成果:
- ETI治疗导致肺功能显著改善 (ppFEV1) 并降低了汗液化物水平.
- 在六个月的ETI治疗后,观察到MIP-3α,GROα,ENA-78和I-TAC的血水平显著降低.
- 发现IL-8水平下降的趋势,但没有达到统计学意义.
结论:
- 通过减少特定的化学激素,ETI治疗显示出抗炎性质.
- 观察到的化学基因变化主要与中性恋炎症有关.
- ETI疗法针对一组独特的化学激素,有助于其在CF中的临床益处.
更多相关视频
10:18Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells
Published on: June 13, 2019
7.5K
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
19.3K
相关概念视频
01:24Cystic Fibrosis: Management
166
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
166
01:23Cystic Fibrosis: Pathogenesis
244
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
244
01:19Antiasthma Drugs: Leukotriene Modifiers
306
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
306